CRISPR Therapeutics has launched a Phase 1 clinical trial to test its experimental cell therapy zugocabtagene geleucel (zugo-cel) in adults with relapsing neuromyelitis optica spectrum disorder (NMOSD), which means the disease is flaring. The Phase 1 study (NCT07804004) is also open to adults with other autoimmune conditions…
Discussion
Last month, some of the world’s leading neurologists, researchers, and scientists working in multiple sclerosis and related neurological diseases like neuromyelitis optica spectrum disorder (NMOSD) arrived in Toronto, Canada, for the 10th Joint ACTRIMS-ECTRIMS Meeting. ECTRIMS, the European Committee for Treatment and Research in Multiple Sclerosis, is…
Discussion
Disability worsening in people with neuromyelitis optica spectrum disorder (NMOSD) is largely driven by relapses, or episodes when new symptoms emerge or existing symptoms worsen, but it may also occur in the absence of such episodes. That’s according to a study analyzing international data from 261 NMOSD patients, which…
NMOSD is a progressive autoimmune disease where the immune system mistakenly attacks nerve cells, affecting the nervous system. Learn more about the disease here.
Scientists do not know the exact underlying cause of NMOSD. Self-reactive antibodies that target AQP4 are known to play a major role. Learn more about what causes the disease here.
When the disease affects the optic nerve (optic neuritis), it can result in pain inside the eye and possibly blurry vision or vision loss. Learn more about the symptoms of the disease here.
Get regular updates to your inbox.
